Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.
Product Name : AER-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2023
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.
Product Name : AER-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2023
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.
Product Name : AER-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2023
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AER-901 is a drug-device combination that is designed to deliver potentially reverse-remodeling therapy with imatinib mesylate deeply and efficiently throughout the diseased tissue of the lung via the FOX® nebulizer.
Product Name : AER-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2022
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Hangzhou Chance Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Aerami will undertake its own PAH clinical development program in the US and other territories for AER-901, drug device combination product pursuant to a worldwide license from Vectura Group plc to develop and commercialize imatinib for the treatment of ...
Product Name : AER-901
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 02, 2021
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Hangzhou Chance Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : FoxWayne Enterprises
Deal Size : $308.0 million
Deal Type : Merger
Details : Proceeds from the transaction will be applied toward advancing AER-901, Aerami’s proprietary inhaled, nebulized formulation of imatinib into a planned Phase 2/3 clinical trial in 2022.
Product Name : AER-901
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 12, 2021
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : FoxWayne Enterprises
Deal Size : $308.0 million
Deal Type : Merger